News

Micron stock rose after UBS said the AI boom has changed the memory chip market — and tripled its price target to a Street high.

Via the deals, Lilly is buying biotechs with lead programmes in preventing shingles, bacteria, and Epstein-Barr Virus.

New Cancer Research Could Be a Massive Game Changer for Ozempic and Mounjaro

Eli Lilly acquired three infectious diseases companies for up to $3.83 billion. Lilly stock ticked higher in response.

Amgen faces LOE headwinds and pricing pressure, yet key growth drugs and biosimilars continue gaining traction.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.7% and the actively trad

Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Eli Lilly (LLY) will acquire three vaccine developers in all-cash deals with a combined value of up

US equity futures were edging higher pre-bell Tuesday as traders monitored the US-Iran situation for

Polymarket traders are watching one biotech more closely than any other for an acquisition. Viking Therapeutics (NASDAQ: VKTX) carries a 38.5% implied probability of being acquired before 2027, with all-time volume above $1.68 million on that single contract. The hook is obesity. Viking’s VK2735 dual GLP-1/GIP agonist is arguably the most advanced obesity asset not ... If Viking Therapeutics Is Acquired, Here’s Who Wins

Eli Lilly announced deals to acquire three biotechnology companies, Curevo, LimmaTech Biologics, and Vaccine Company for roughly $3.8 billion in total consideration.

Eli Lilly and Company (NYSE:LLY) is one of the best medical stocks to invest in according to billionaires. Eli Lilly and Company (NYSE:LLY) received a rating update from Truist on May 1, with the firm maintaining a Buy rating on the shares with a price target of $1,281. It stated that the company’s retatrutide Phase 3 […]

Walmart's recent run of outperformance could be coming to an end.

The deals give Lilly vaccines targeting shingles, bacterial pathogens, and Epstein-Barr virus as it expands beyond weight loss drugs

Eli Lilly agreed to acquire three vaccine developers in deals worth up to nearly $4 billion combined, the company told The Wall Street Journal. Indianapolis-based Lilly has agreed to acquire Curevo, LimmaTech Biologics and Vaccine Co. Curevo is developing a shingles vaccine that Lilly believes could be as effective as the current standard but with reduced side effects, said Daniel Skovronsky, Lilly’s chief scientific and product officer.

(Bloomberg) -- US equity futures extended gains and Treasuries rallied as investors remained hopeful that the latest American strikes on Iran won’t derail talks to end the Middle East conflict. Most Read from BloombergNvidia CEO Urges Super Micro to Tighten Up on ComplianceTrump Doctor Visit Renews Health Scrutiny as 80th Birthday NearsTrump Says He’ll Announce Negotiated Deal With Iran ShortlyRubio Sees Good News Coming on Hormuz as Iran Talks ContinueUS, Iran Inch Toward Deal as Gaps Remain on

These players are seeing exciting results in clinical trials.

LLY's stock is still down year-to-date as AI-driven narratives have captured the bulk of investor attention and capital in 2026.

It may be too late for Viking to take on the "dark horse" role in the GLP-1 wars.

The efficacy of Eli Lilly's new, still-in-development GLP-1 drug is gaining attention, but don't forget its older GLP-1 drugs just yet.

Eli Lilly and Co (NYSE:LLY) last week reported late-stage weight loss data for retatrutide, which UBS analysts highlighted showed “solid strong weight loss efficacy” and were broadly in line with expectations ahead of further detail at the American Diabetes Association meeting. UBS...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

The Vanguard Dividend Appreciation Index Fund ETF Shares (NYSEARCA:VIG) is having a quieter year than its big-cap dividend-growth reputation suggests, with shares around $229 and a 5% year-to-date gain trailing the broader market. The 12-month picture is stronger at almost 17%, but the recent flattening tells you something important: VIG’s dividend-growth playbook is being squeezed ... VIG Investors: Watch the 10-Year Treasury Yield This Week—4.75% Is the Danger Line

The pharma giant is taking steps to expand its portfolio.

With a 5-year dividend growth rate of 15.23%, Eli Lilly and Company (NYSE:LLY) is included among the 10 Best Dividend Growth Stocks to Buy and Hold for 3 Years. In a CNBC report published on May 21, Eli Lilly and Company (NYSE:LLY) said its experimental obesity drug, retatrutide, cleared a major late-stage clinical trial. The results […]

Go beyond the broad index and find which segment of healthcare best suits your portfolio needs now.

This breakdown considers whether Eli Lilly at around US$1,065 a share may still offer value or whether the best of the opportunity may already be behind it, with a focus on what the current price might imply. Over the short term, the stock has returned 6.0% over the past week and 15.6% over the past month. Year to date it is down 1.4%, and the 1 year return stands at 50.3%, with a very large gain over 5 years of around 7x. Recent headlines have centered on Eli Lilly's role in large scale...

Eli Lilly and Company (NYSE:LLY) is one of the best low risk stocks to buy in 2026. On May 21, Lilly’s Phase 3 TRIUMPH-1 trial evaluated retatrutide, an investigational once-weekly triple hormone receptor agonist (GIP/GLP-1/glucagon). The 80-week study involved 2,339 adults with obesity or overweight and at least one comorbidity, excluding diabetes. All doses met […]

Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the legendary stocks that return 100 times your money.

Stocks were up sharply to end the week as NVIDIA’s forward guidance showed tangible demand to support AI infrastructure and overshadowed mixed retail reports